Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda

Merck & Co., Inc. MRK announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion, recommending marketing approval for an improved dosing schedule of its blockbuster anti-PD-1 therapy, Keytruda.